Sage Therapeutics Inc
NASDAQ:SAGE 3:59:52 PM EDT
| Market Cap (Intraday) | 2.44B |
| Current PE | 3.83 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $44.03 |
| 50-Day MA | $56.86 |
| 200-Day MA | $72.84 |
Sage Therapeutics Inc Stock, NASDAQ:SAGE
215 1st Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.299.8380
Number of Employees: 298
Description
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.